Argos Therapeutics, Inc.

ARGSQ

US0402212023

Pharmaceuticals

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-6.22%	+78.50%

2019	Argos Therapeutics, Inc. Went Out of Business	CI
2019	First Amended Liquidation Plan Approved for Argos Therapeutics, Inc.	CI

Lee F. Allen Joins Argos Therapeutics as Chief Medical Officer

January 20, 2016 at 01:30 pm

Argos Therapeutics Inc. announced that Lee F. Allen, MD, PhD, has joined the company as chief medical officer. Lee most recently serving as chief medical officer for Spectrum Pharmaceuticals.

Latest news about Argos Therapeutics, Inc.

Argos Therapeutics, Inc. Went Out of Business	24/09/19	CI
First Amended Liquidation Plan Approved for Argos Therapeutics, Inc.	24/09/19	CI
First Amended Liquidation Plan Filed by Argos Therapeutics, Inc.	30/08/19	CI
Revised Disclosure Statement Approved on Interim Basis for Argos Therapeutics, Inc.	21/03/19	CI
Liquidation Plan and Disclosure Statement Filed by Argos Therapeutics, Inc.	15/03/19	CI
Genexine Inc. and SCM Lifescience Co. completed the acquisition of substantially all of the assets of Argos Therapeutics Inc.	12/02/19	CI
Motion for Asset Sale Approved for Argos Therapeutics, Inc.	23/01/19	CI
Notice of Successful Bidder Filed by Argos Therapeutics, Inc.	22/01/19	CI
Genexine Inc. and SCM Lifescience Co. entered into an asset purchase agreement to acquire substantially all of the assets of Argos Therapeutics Inc. for $11.3 million.	21/01/19	CI
CELLSCRIPT, LLC and Immune and Cell Therapies, LLC cancelled the acquisition of substantially all of the non-cash assets of Argos Therapeutics, Inc..	21/01/19	CI
Bidding Procedure Approved for Argos Therapeutics, Inc.	20/12/18	CI
Argos Therapeutics, Inc. will Change its Ticker to ARGSQ from ARGS	06/12/18	CI
Argos Therapeutics, Inc. Announces Management Changes	03/12/18	CI
Argos Therapeutics, Inc. Filed for Bankruptcy	30/11/18	CI
Motion for Asset Sale Filed by Argos Therapeutics, Inc.	30/11/18	CI
CELLSCRIPT, LLC and Cell Therapies, LLC entered into an asset purchase agreement to acquire Substantially All of the Non-Cash Assets of Argos Therapeutics, Inc. for approximately $1.7 million.	29/11/18	CI
Argos Therapeutics, Inc.(NasdaqCM:ARGS) dropped from S&P TMI Index	26/04/18	CI
Argos Therapeutics, Inc. Announces Resignation of Sander van Deventer as Board of Directors	24/04/18	CI
Argos Therapeutics, Inc.(NasdaqCM:ARGS) dropped from NASDAQ Composite Index	24/04/18	CI
Argos Therapeutics, Inc. announced that it has received $0.45 million in funding from Lummy (Hong Kong) Co., Ltd.	19/04/18	CI
Argos Therapeutics, Inc. Reports Results of Interim Analysis of the Adapt Trial and Announces Review of Strategic Alternatives	19/04/18	CI
Argos Therapeutics Announces Review of Strategic Alternatives	19/04/18	CI
Argos Therapeutics, Inc. Announces Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2017	02/04/18	CI
Argos Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	01/04/18	CI
Transcript : Argos Therapeutics, Inc. - Special Call	06/02/18

Chart Argos Therapeutics, Inc.

Duration

Period

More charts

Argos Therapeutics, Inc. (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company's Arcelis technology platform utilizes biological components from a patient's own cancer cells or virus to generate individualized immunotherapies. The Company is engaged in the development of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC), and other cancers. It is conducting a pivotal Phase III clinical trial of AGS-003 plus sunitinib or another targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment (SPA). It is engaged in the development of AGS-004 for the treatment of Human Immunodeficiency Virus (HIV). It has conducted over three clinical trials of AGS-004, including a Phase IIb clinical trial, Phase IIa clinical trial and Phase I clinical trial.

Sector

Pharmaceuticals

More about the company

Sector Biopharmaceuticals

	1st Jan change	Capi.
ARGOS THERAPEUTICS, INC.	+78.50%	567K
CSL LIMITED	-1.62%	89.22B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	40.49B
BIOGEN INC.	-15.73%	32.79B
UCB	+64.13%	26.23B
BIOMARIN PHARMACEUTICAL INC.	-21.28%	14.52B
INCYTE CORPORATION	-8.50%	13.09B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-44.07%	11.6B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-13.06%	11.5B
SWEDISH ORPHAN BIOVITRUM AB	+4.94%	8.82B

Biopharmaceuticals

Argos Therapeutics, Inc.

Equities

ARGSQ

US0402212023

Pharmaceuticals

Lee F. Allen Joins Argos Therapeutics as Chief Medical Officer

Latest news about Argos Therapeutics, Inc.

Chart Argos Therapeutics, Inc.

Company Profile

Sector Biopharmaceuticals